During its February 2024 meeting, the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency reminded healthcare professionals of the risk of serious and potentially fatal adverse reactions with Paxlovid when used in combination with certain immunosuppressants.
The FPS Public Health and the FAMHP invite you to participate in the public consultation on a clinical trial of the genetically modified medicine SRP-9003 for the treatment of limb girdle muscular dystrophy. The public consultation runs from 14 February 2024 to 14 March 2024.
During its January 2024 meeting, the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency recommends precautionary measures regarding the potential risk of neurodevelopmental disorders in children born to men treated with valproate medicines.
Medication errors can occur at any stage in the medicine circuit: during prescribing, dispensing, storing, preparing and administering. They pose a major public health problem.
Marketing authorisation holders have until 29 February 2024 to submit annual sales volume data for veterinary medicinal products for 2023.
The FAMHP and Sciensano are making available a Belgian regulatory guidance on the use of genetically modified organisms in clinical trials.
From 1 January to 30 June 2024, Belgium is holding the presidency of the Council of the European Union. The presidency in the area of public health will focus on three major themes: care, preparedness and protection. The FAMHP will use this opportunity to put our priorities on the European agenda and to help define European health policy for the coming years.
The Summary of Product Characteristics (SPC) and package leaflet for gabapentin-containing medicines (Neurontin and generics in Belgium) have been updated following analyses of the risks of misuse, abuse and dependence.